Gary Sams, Ph.D,
Founder & CEO
Progenitor Gary R. Sams, Ph.D. is the CEO and founder of Progenitor and is responsible for all company operations in particular providing guidance to the proposed project. Dr. Sams has extensive and deep experience in the research tools, diagnostics, and biopharma development industries. He is CEO and founder (1994) of Beachhead LLC, a life sciences management consulting firm, which specializes in market and technology assessment of tools, molecular diagnostics, and biopharma discovery markets and products. Dr. Sams among others has been directly involved in projects associated with applications of PCR, Next-Gen DNA sequencing, and other genomic and proteomic technologies.
Tim Graham, M.D.
Advisor, University of Utah, Professor of Medicine
Progenitor Tim Graham, M.D. is the CSO and co-founder of Progenitor. He oversees scientific strategy and day-to-day operations of Progenitor’s laboratory. Dr. Graham is Associate Professor of Medicine, Biochemistry, and Nutrition at the University of Utah. He is a Senior Investigator in the Molecular Medicine Program, with 20 years’ experience managing NIH- and VA-funded research programs. His primary area of academic research relates to immune system dysfunction in obesity, type 2 diabetes, and related cardiovascular complications. He has extensive expertise in cell biology and the use of embryonic stem cell engineering to create new model organisms for studying human diseases. Dr. Graham trained at Harvard Medical School, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children’s Hospital, and Joslin Diabetes Center.
Stefan Pulst, M.D., Ph.D
Founder, University of Utah Professor, Chair of Neurology
Progenitor Dr. Stefan Pulst is a founding scientist of Progenitor Life Sciences, responsible for the research and development behind Progenitor’s novel MatisseTM reprogramming vector. He is Professor and Chair of the Department of Neurology at the University of Utah in Salt Lake City. He received his neurological training at the Medizinische Hochschule Hannover in Germany and in the Longwood Program at Harvard Medical School in Boston. He then joined Dr. Dennis Deen at the UCSF Brain Tumor Research Center to study in vitro cytotoxicity models and subsequently did a postdoctoral fellowship in neurobiology at UCSF, where he worked with Dr. Earl Mayeri on peptidergic neurotransmission in Aplysia. Prior to moving to the University of Utah in 2007, he was the Carmen and Louis Warschaw Chair in Neurology at Cedars-Sinai Medical Center in Los Angeles and Professor of Medicine, Neurology, and Neurobiology at the UCLA School of Medicine.
Baird Life Sciences, Private Equity Management
Progenitor Mr. Jeffrey Fink sits on the Board of Directors for Progenitor and provides guidance on commercialization and financing strategies. Mr. Fink has over 20 years of finance and strategy experience within the life science and healthcare industry. Mr. Fink is currently the managing director of Gambel Oaks Advisors, LLC, a strategic and financial advisory firm dedicated to the life sciences and allied industries. Mr. Fink spent over twenty years in the investment banking industry advising life science clients in the U.S. and Europe on the full range of financing and strategic advisory assignments.
Outside Business Advisor, Ex CEO Affymetrix
Progenitor Mr. Frank Witney is an outside business advisor for Progenitor and provides commercialization and financing strategy input. Dr. Witney brings more than 30 years of experience in leadership and innovation in life science research, products, and diagnostic and analytical instruments to Affymetrix. He previously served at Affymetrix as Executive Vice President and Chief Commercial Officer following Affymetrix’ acquisition of Panomics Inc., a quantitative biology company he pioneered for six years as President and Chief Executive Officer. Prior to his return to Affymetrix, Dr. Witney was President and Chief Executive Officer of Dionex Corp., leading this ion and high performance liquid chromatography company to a hugely successful acquisition by Thermo Fisher Scientific, Inc.
Outside Business Advisor, Ex Aastrom CEO, ex Arboretum VC Partner
Progenitor Mr. George Dunbar is an independent director for Progenitor adding commercialization and provides governance and financing guidance for the company. He has extensive healthcare and life sciences operating experience, and has served as a Director or CEO with both private and public life science companies in Diagnostics, Specialty Pharma, Cell Therapy, and Biologics, two where he led initial public offerings. George is currently CEO of ISTO Technologies, a private equity owned intelligent biologics business focused on evidence driven products serving the orthopedic markets. Prior to ISTO, he served as a Venture Partner with Arboretum Ventures, a leading healthcare venture capital Fund. George is also a Director of Capricor Therapeutics (CAPR).